Preferred Label : cobimetinib;

MeSH note : has antineoplastic activity; structure in first source;

CISMeF synonym : (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; GDC-0973;

Related MeSH term : XL518;

Is substance : O;

UNII : ER29L26N1X;

Details


Main resources

You can consult :


https://ansm.sante.fr/informations-de-securite/zelboraf-cotellic-v-rappel-du-risque-datteintes-opthalmiques-et-de-leur-prise-en-charge
2018
false
false
false
France
French
pharmacovigilance note
retinal diseases
vision disorders
cobimetinib
continuity of patient care
mass screening
risk
guidelines for drug use
pharmacovigilance
uveitis
cobimetinib
indoles
sulfonamides
azetidines
piperidines
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_2620147/fr/cotellic
http://www.has-sante.fr/portail/jcms/c_2620147/fr/cotellic-cobimetinib-anti-mek-inhibiteur-de-proteine-kinase
2016
false
false
false
France
French
cobimetinib
cobimetinib
vemurafenib
melanoma
neoplasm metastasis
administration, oral
MAP kinase kinase 1
antineoplastic agents
antineoplastic agents
adult
continuity of patient care
treatment outcome
antineoplastic combined chemotherapy protocols
melanoma
BRAF gene mutation
evaluation of the transparency committee
Metastatic Melanoma
Unresectable Malignant Neoplasm
guidelines for drug use
cobimetinib
Tyrosine Kinase Inhibitors
cobimetinib
cobimetinib
azetidines
piperidines
azetidines
piperidines
indoles
sulfonamides
Vemurafenib

---
https://www.ema.europa.eu/medicines/human/EPAR/Cotellic
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
cobimetinib
cobimetinib
vemurafenib
melanoma
neoplasm metastasis
administration, oral
MAP kinase kinase 1
antineoplastic agents
antineoplastic agents
adult
continuity of patient care
drug evaluation
syndication feed
drug approval
europe
treatment outcome
drug interactions
pregnancy
breast feeding
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
melanoma
BRAF gene mutation
cobimetinib
Cobimetinib/Vemurafenib Regimen
Tyrosine Kinase Inhibitors
cobimetinib
cobimetinib
azetidines
piperidines
azetidines
piperidines
indoles
sulfonamides
Vemurafenib

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.